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Background: Knowledge of the burden of healthcare-associated infections (HAI) and antibiotic resistance is
important for resource allocation in infection control. Although national surveillance networks do not routinely
cover all HAIs due to multidrug-resistant bacteria, estimates are nevertheless possible: in the EU, 25,000 patients die
from such infections annually. We assessed the burden of HAIs due to multidrug-resistant bacteria in Finland in
2010.
Methods: By combining data from the National Infectious Disease Registry on the numbers of bacteremias caused
by Staphylococcus aureus, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Enterobacter spp.,
Pseudomonas aeruginosa and Acinetobacter spp., and susceptibility data from the National Antimicrobial Resistance
Network and the Finnish Hospital Infection Program, we assessed the numbers of healthcare-associated
bacteremias due to selected multidrug-resistant bacteria. We estimated the number of pneumonias, surgical site
and urinary tract infections by applying the ratio of these infections in the first national prevalence survey for HAI in
2005. Attributable HAI mortality (3.2%) was also derived from the prevalence survey.
Results: The estimated annual number of the most common HAIs due to the selected multidrug-resistant bacteria
was 2804 (530 HAIs per million), 6% of all HAIs in Finnish acute care hospitals. The number of attributable deaths
was 89 (18 per million).
Conclusions: Resources for infection control should be allocated not only in screening and isolation of carriers of
multidrug-resistant bacteria, even when they are causing a small proportion of all HAIs, but also in preventing all
clinical infections.
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According to the analysis of European Centre for Disease
Prevention and Control (ECDC) and European Medicines
Agency (EMEA) in 2007, an estimated number of deaths
attributable to infections due to selected multidrug-
resistant bacteria, Staphylococcus aureus, Enterococcus
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was about 25,000 [1]. Approximately 37,000 patients die
as a direct consequence of a hospital-acquired infection
and an additional 111,000 die as an indirect consequence
of the hospital-acquired infection annually [2]. As deaths
due to resistant microbes are generally associated with
healthcare-associated infections (HAI), antibacterial re-
sistance could be responsible for up to half of HAI deaths.
ECDC/EMEA analysis also reported the extra healthcare
cost and productivity losses due to resistant bacteria in
the EU and it was at least 1.5 billion each year [1].
These estimates give an overview of the magnitude of
the problem of antibacterial resistance and HAI inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trators who make resource allocation for infection con-
trol. However, the proportion of multidrug-resistant
isolates among these bacteria varies between countries,
and the data cannot be applied directly to different EU
countries.
Earlier we estimated that annually approximately 6%
of all patients in acute care hospitals in Finland get at
least one HAI, and 3.2% of HAI patients die as a direct
or indirect consequence of infection [3]. In the national
prevalence survey in 2005, only 1.5% of microbiologically
confirmed HAIs were due to tobramycin-resistant
Pseudomonas aeruginosa, methicillin resistant S. aureus
(MRSA) or extended spectrum β-lactamase (ESBL) pro-
ducing Enterobacteriacae bacteria [4]. Thus most HAI
deaths in Finland are most probably due to non-
multidrug-resistant bacteria.
In Finland, several tools are available for the surveil-
lance of antibacterial resistance, some of which are na-
tionwide and others sentinel. However, these data
sources cannot directly serve to assess the burden of
HAI due to multidrug-resistant bacteria, since
laboratory-based surveillance does not distinguish be-
tween colonisation and clinical infections, and since
among clinical infections, only bacteremias are surveyed
nationwide. By using various national surveillance and
survey data, we estimated the number of HAIs and HAI
mortality based on a set of the best surveyed multidrug-
resistant bacteria in Finland in 2010.
Methods
Data sources included the following national and senti-
nel surveillance programmes. The National Infectious
Disease Registry (NIDR) collects data on invasive bacter-
ial isolates from blood and cerebrospinal fluid, all iso-
lates of MRSA, vancomycin-resistant enterococci (VRE)
and all isolates of E. coli and Klebsiella pneumoniae
which are intermediately susceptible (I) or resistant (R)
to third generation cephalosporins (potential ESBL pro-
ducers). Since 2011, Enterobacteriacae isolates non-
susceptible (I/R) to carbapenems were also surveilled;
thus data for 2010 was unavailable. During 2011, how-
ever, notifications mainly entailed colonisations, rather
than infections. The Finnish study group for antimicro-
bial Resistance (FiRe) is a network of 24 clinical micro-
biology laboratories (covering >95% of all clinical
laboratories that process blood cultures in Finland) that
collect susceptibility data on 15 bacteria. Of the 24 FiRe
laboratories, 20 report susceptibility data on the invasive
isolates of seven indicator pathogens to the European
Antimicrobial Resistance Surveillance System (EARS-
Net). The Finnish Hospital Infection Program (SIRO), a
sentinel network of 15 hospitals, has surveilled HAI, in-
cluding nosocomial bloodstream infections (BSI) andsurgical site infections (SSI) in selected surgical proce-
dures since 1999. SIRO performed the first national
prevalence survey of HAIs in 2005, which covered all
HAI types and the outcomes of the study patients in 30
acute care hospitals [4].
The NIDR provided the total number of bacteremia
cases caused by S. aureus, Enterococcus faecium, E. coli,
K. pneumoniae, Enterobacter spp., P. aeruginosa and
Acinetobacter spp. in 2010 [5]. Resistance percentages to
antibiotics were identified as follows: from the NIDR, for
MRSA and VRE as well as I/R for third generation
cephalosporins in E. coli and K. pneumonia; from SIRO
and FiRe, I/R for amikacin in P. aeruginosa, for third
generation cephalosporins in Enterobacter spp. and for
carbapenems in Acinetobacter spp. All these resistant
bacteria were considered as multidrug-resistant isolates.
The national prevalence survey of HAIs in 2005 pro-
vided the number of pneumonias, SSI and urinary tract
infections (UTI) in relation to BSI [4].
By applying the above mentioned resistance percen-
tages to the numbers of bacteremias in the NIDR, we
estimated the number of BSI cases due to these resistant
bacteria. We estimated the number of other common
types of HAIs (pneumonia, as well as SSI and UTI) due
to these resistant bacteria by multiplying the number of
bacteremias in the NIDR by their corresponding ratio in
the national prevalence survey.
The dates and causes of death and 28-day attributable
mortality due to HAI in the prevalence survey cohort
were obtained from the National Population Information
System by using the patient’s national identity code, as
described earlier [3]. We estimated the number of deaths
from these infections by applying an average attributable
mortality of 3.2% [3].
We calculated 95% Bayesian confidence intervals
(credible intervals) using Markov Chain Monte Carlo
simulations. We used coefficients 0.5 and 1.5 to describe
uncertainty in the number of BSI due to resistant bac-
teria as well as in the proportion of other types of
infection.
Results
Percentages of resistance to the antibiotics in blood iso-
lates were: MRSA 1.9% (26/1370), VRE 1.1% (3/278),
third generation cephalosporins for E. coli 3.4% (112/
3211), and for K. pneumoniae 3.2% (16/504), and for
Enterobacter spp. 34.0% of 259 isolates, amikacin for P.
aeruginosa 5.0% of 318 isolates and carbapenems for
Acinetobacter spp. 3.3% of 34 isolates (Table 1).
In the prevalence survey among all 753 infections, the
numbers of the most common infection types were as
follows: 44 (6%) primary BSIs, 110 (15%) pneumonias,
215 (29%) SSIs, 103 (15%) symptomatic UTIs and 281
(37%) other. In relation to BSIs, the corresponding ratio
Table 1 Observed* of estimated annual numbers of healthcare-associated infections due to multidrug-resistant
bacteria
Numbers of HAIs (95% confidence interval)







E. coli K. pneumoniae Enterobacter spp.
Blood stream infection 26* (17–37) 3* (1-7) 112* (92–134) 16* (10–25) 88 (47–136) 16 (9–25) 1 (12)
Pneumonia 65 (29–114) 8 (1–20) 280 (142–440) 40 (16–75) 220 (87–415) 40 (16–75) 3 (1-5)
Surgical site infection 127 (58–22) 15 (3–40) 549 (278–862) 78 (33–147) 431 (172–814) 78 (32–147) 5 (2-10)
Urinary tract infection 60 (27–105) 7 (1–16) 258 (131–405) 37 (15–69) 202 (81–381) 37 (15–69) 2 (1-5)
All 278 (159–434) 33 (6–81) 1199 (795–1654) 171 (87–287) 941 (458–1584) 171 (86–287) 11 (5–19)
Footnote: HAI=healthcare-associated infection, MRSA=methicillin resistant Staphylococcus aureus, VRE=vancomycin resistant Enterococcus faecium,
I/R = intermediately suscaptible or resistant.
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monias, 4.9 (215/44) for SSIs and 2.3 (103/44) for UTIs.
The estimated annual numbers of these four common
types of HAIs due to the resistant bacteria were calcu-
lated by multiplying the number of the BSIs by these in-
fection ratios. Thus for example, the estimated number
of pneumonias due to MRSA was 26 x 2.5 = 65, and
numbers of SSIs and UTIs due to MRSA were 26 x 4.9 =
127 and 26 x 2.3 = 60, respectively (Table 1).
The estimated total annual numbers of the four HAI
types due to MRSA, VRE, third generation cephalo-
sporin I/R E. coli and K. pneumoniae and Enterobacter
spp., as well as amicacin I/R P. aeruginosa and carbape-
nem I/R Acinetobacter spp. were 278, 33, 1199, 171, 941,
171 and 11, respectively (Table 1), for a total of 2804
(530 HAIs caused by resistant bacteria per million popu-
lation). The estimated total annual number of attribut-
able deaths due to these infections was 89 (18 per
million population).
Conclusions
This study represents the first attempt to estimate the
burden of HAIs due to multidrug-resistant bacteria in
Finland. The annual number of HAIs in acute care hos-
pitals in Finland is at least 50 000 [3]. Here we show,
that at approximately 2800 (6%) of them may be due to
multidrug-resistant bacteria. The HAI morbidity and
mortality due to multidrug-resistant bacteria is, in Fin-
land, thus far relatively low and lower than the figures in
the EU as a whole [1], but shows differences depending
on the resistant bacterium. The methodology we used
was based on the work presented by the ECDC/EMEA
and might be applied also by other countries in their
burden assessments [1].
The results we present here are a rough estimate. True
figures of the burden of all HAIs due to all resistant
microbes cannot directly be achieved through any na-
tional surveillance methods generally used. This data
cannot easily be collected at a hospital level either: e.g.prevalence surveys are vulnerable for chance, collection
of full cover resistance data is laborious in prevalence
survey, and often only half of HAIs are microbiologically
confirmed. Therefore, an estimate of the burden is prac-
tically the best we can achieve to date. In the future, e.g.
enhanced on line HAI reporting e.g. by using compul-
sory computerized reporting of antibiotic prescribing
indications (HAI, community-acquired infection or
prophylaxis) and automated combination of microbio-
logical data of causative pathogens might improve the
data coverage. To get the most applicable data now, we
chose national data sources e.g. to cover estimates of
HAIs and deaths. The national prevalence data were
quite representative of Finnish acute care hospitals: over
8,000 adult inpatients in all five tertiary care hospitals,
and all 15 secondary care hospitals as well as 10 (25% of
all) other acute care hospitals took part in the voluntary
survey. The resistance data from laboratories also well
covered the whole country.
There are, however, several limitations in our esti-
mates. Firstly, we included only seven microbes and four
infection types. In the national prevalence survey data,
the selected microbes, S. aureus, Enterococcus spp.,
E. coli, K. pneumoniae, Enterobacter spp., P. aeruginosa
and Acinetobacter spp., caused 48% of all microbiologic-
ally conformed HAIs and comprised 34% of all causative
microbes [4]. Selected infection types covered 63% of all
HAIs. We excluded coagulase-negative staphylococci, as
in the ECDC/EMEA report [1], due to its various resist-
ance patterns and relatively low virulence, and pneumo-
cocci because a majority of these infections are
community-acquired [6]. Rice et al. grouped E. faecalis
and faecium, S. aureus, K. pneumoniae, A.baumannii,
P. auruginosa and the Enterobacter species as the most
common nosocomial pathogens that escape the effects
of many antibiotics, and used the acronym ESKAPE [7].
Secondly, we used a prevalence survey, not incidence
data, to estimate the HAI numbers and distribution. In
the prevalence survey, because HAI prolongs the length
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likely to be overrepresented in relation to mild infec-
tions, like UTIs. In addition, the prevalence data was
from 2005, and lengths of stay may have shortened after
that, also affecting the proportions of different HAI.
Thirdly, we applied the same ratio of other infections
to BSIs for all microbes. In fact, Enterobacteriaceae are
usually more prone to cause UTIs, and MRSA causes
SSI. In addition, the NIDR surveillance data included
both primary and secondary BSIs, but the prevalence
survey included only primary BSI, which can affect the
estimated distribution of infection types, leading to an
overestimation of the number other infections by ap-
proximately 20%.
Fourthly, infections caused by ESBL producing
gram-negatives, especially E. coli UTIs, can also be com-
munity-acquired, although severe and complicated infec-
tions, such as bacteremias [8], may more likely be
healthcare-associated. In reports from different hospital
settings from the years 1999–2007, the proportion of
community-associated BSIs (i.e. in patients with no pre-
vious hospitalizations or healthcare-associated risk fac-
tors) among all BSIs due to ESBL producing E. coli has
been low but variable: 1.6% in Italy, 3% in Finland, 19%
in Spain but reached 42% in Canada [9-12]. This ten-
dency of having the most bacteremic complications dur-
ing hospital care also applies to MRSA, although
community-acquired skin and soft tissue infections are
common [13]. Infections due to other multidrug-
resistant microbes in our study can mainly be considered
healthcare-associated. We estimate that including all
BSIs due to multidrug-resistant bacteria as HAIs leads
to an overestimation of HAIs due to these bacteria by
another 10%. Finally, the average attributable mortality
of 3.2% from the Finnish prevalence survey reflects HAI
mortality mostly due to sensitive bacteria, which may
lead to underestimation of mortality due to multidrug-
resistant pathogens even as much as 50%.
Estimates of the burden of HAI due to antibiotic-
resistant microbes are important for those who allocate
resources or prioritize the work of an infection control
team. In countries with low prevalence of antibacterial
resistance, a lot of resources of infection control are
often allocated to prevent the spread of resistant
microbes, i.e. contact tracing, screening patients for col-
onisation, applying isolation precautions and occasion-
ally also on decolonization. The emergence of
carbapenemase-producing Enterobacteriaceae is an ex-
ample of the importance of timely identifying risk
groups for screening and action. However, all infection
control resources should not be focused on one microbe
or resistance pattern only, such as MRSA or ESBL.
Especially, if the prevalence of antibacterial resistance
is high, these narrow spectrum interventions areinsufficient to prevent clinical complications. Infection
control interventions including evidence-based guide-
lines, increasingly implemented as “care bundles” and
“check lists”, meticulous hand hygiene in all patient care,
prudent use of antimicrobials are needed to reduce HAIs
in general, along with those caused by multidrug-
resistant bacteria. This approach has a greater impact on
mortality, morbidity and costs than does screening alone
[14,15].
As most HAIs are due to endogenous bacteria, and be-
cause e.g. in Finland, up to 94% of HAIs still stem from
non-multidrug-resistant bacteria, we should not forget
infection-type specific prevention when allocating
resources in low prevalance countries either. This is es-
pecially important considering, for example ESBL produ-
cing bacteria, which are increasingly prevalent in the
community and cause preventable catheter-associated
bacteremic UTIs in hospital settings.
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